HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yun Ju Bae Selected Research

CT-P17

11/2022Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis.
1/2021Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yun Ju Bae Research Topics

Disease

5Rheumatoid Arthritis
11/2022 - 08/2017
2Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
11/2018 - 08/2017
1Neutropenia
08/2017
1Wounds and Injuries (Trauma)
02/2016

Drug/Important Bio-Agent (IBA)

4Biosimilar PharmaceuticalsIBA
01/2021 - 08/2017
3CT-P10IBA
12/2019 - 08/2017
3Rituximab (Mabthera)FDA Link
12/2019 - 08/2017
2CT-P17IBA
11/2022 - 01/2021
2Adalimumab (Humira)FDA Link
11/2022 - 01/2021
1Citric Acid (Citrate)FDA LinkGeneric
01/2021
1Vincristine (Oncovin)FDA LinkGeneric
08/2017
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
08/2017
1Prednisone (Sone)FDA LinkGeneric
08/2017
1Becaplermin (PDGF-BB)FDA Link
02/2016
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
02/2016

Therapy/Procedure

1Intravenous Infusions
08/2017
1Microspheres (Microsphere)
02/2016